FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to medicine, namely cardiology, and concerns treating non-ST elevation myocardial infarction. That is ensured by administering (2R,3R)-2-(3-carbamimidoyl benzyl)-3-[4-(1-oxypyridinyl)benzoylamino]butyric acid methyl ester (otamixaban) or its pharmaceutically acceptable salt in a dose of 0.070 mg/kg - 0.14 mg/kg.
EFFECT: administering Otamixaban in this dosage range provides the effective treatment of non-ST elevation myocardial infarction, including in the patients aged 65 years old and more, as well as in the patients suffering renal failure, and has no side effects.
13 cl, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CARE OF PATIENTS WITH ACUTE CORONARY SYNDROME UNDER CONDITIONS OF MEDICAL INSTITUTION WITH SPECIALIZED DEPARTMENT OF PERCUTANEOUS CORONARY INTERVENTIONS | 2015 |
|
RU2641851C2 |
| BENZOATE SALT OF OTAMIXABAN | 2012 |
|
RU2597423C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2019 |
|
RU2813780C2 |
| TREATMENT OF HYPERTENSION AND/OR PREVENTION AND TREATMENT OF HEART FAILURE IN MAMMAL, RECEIVING ANTICOAGULANT THERAPY | 2011 |
|
RU2564941C2 |
| TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTERING TIROFIBAN | 2010 |
|
RU2539398C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
| METHOD OF ACUTE MYOCARDIAL INFARCTION TREATMENT | 2008 |
|
RU2365380C1 |
| PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND INHIBITORS OF NEUTRAL ENDOPEPTITAS (NEP) | 2003 |
|
RU2334513C2 |
| METHOD OF DIABETES TREATMENT | 2007 |
|
RU2442585C2 |
